{"id":9690,"date":"2025-03-12T00:54:23","date_gmt":"2025-03-12T00:54:23","guid":{"rendered":"https:\/\/www.lupuscanada.org\/essai-clinique-sur-lobexelimab-pour-le-lupus-erythemateux-dissemine-led\/"},"modified":"2025-03-14T14:08:41","modified_gmt":"2025-03-14T14:08:41","slug":"essai-clinique-sur-lobexelimab-pour-le-lupus-erythemateux-dissemine-led","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/essai-clinique-sur-lobexelimab-pour-le-lupus-erythemateux-dissemine-led\/","title":{"rendered":"Essai clinique sur l\u2019obexelimab pour le lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED)"},"content":{"rendered":"

[et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.27.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2024\/08\/Custom-Gradient-1080×1080@2x.png\u00a0\u00bb custom_margin=\u00a0\u00bb-14px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.27.3″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb30px||||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0″]<\/p>\n

Essai clinique sur l\u2019obexelimab pour le lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED)<\/strong><\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb||15px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Recrutement actuel de participants<\/strong><\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb||15px||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0″]<\/p>\n

Lupus Canada partage de l\u2019information au sujet d\u2019un essai clinique qui recrute actuellement des personnes atteintes de lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED)<\/strong> dans le cadre des essais cliniques de Richmond<\/strong>. Cette \u00e9tude de phase 2<\/strong> vise \u00e0 \u00e9valuer l\u2019innocuit\u00e9 et la tol\u00e9rabilit\u00e9 de l\u2019Obexelimab<\/strong>, un anticorps monoclonal con\u00e7u pour r\u00e9guler l\u2019activit\u00e9 des lymphocytes B chez les patients atteints de lupus. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00a0\u00bb1_2,1_2″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb24px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_2″ _builder_version=\u00a0\u00bb4.27.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/Half-Page-Print-15-Nov-2024.png\u00a0\u00bb title_text=\u00a0\u00bbEssai clinique sur l\u2019obexelimab pour le lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED)\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb module_alignment=\u00a0\u00bbcenter\u00a0\u00bb height=\u00a0\u00bb459px\u00a0\u00bb custom_margin=\u00a0\u00bb-4px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_2″ _builder_version=\u00a0\u00bb4.27.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb8px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

D\u00e9tails cl\u00e9s :<\/strong><\/h5>\n
    \n
  • Emplacement:<\/strong> Essais cliniques \u00e0 Richmond<\/li>\n
  • Phase de l\u2019\u00e9tude :<\/strong> Phase 2<\/li>\n
  • Traitement:<\/strong> Administration sous-cutan\u00e9e d\u2019Obexelimab<\/li>\n
  • Co\u00fbt:<\/strong> La participation est gratuite ; Une indemnisation peut \u00eatre disponible<\/li>\n
  • \u00c9ligibilit\u00e9:<\/strong> Les patients doivent r\u00e9pondre \u00e0 des crit\u00e8res d\u2019inclusion sp\u00e9cifiques (voir ci-dessous)<\/li>\n<\/ul>\n

    <\/span><\/p>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb15px||15px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

    Crit\u00e8res d\u2019admissibilit\u00e9 :<\/strong><\/h5>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00a0\u00bb1_2,1_2″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-22px||15px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_2″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb||0px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

    Principaux crit\u00e8res d\u2019inclusion :<\/strong><\/h6>\n
      \n
    • \u00c2ge :<\/strong> 18-70 ans<\/li>\n
    • Diagnostic:<\/strong> Diagnostic de LED confirm\u00e9 depuis au moins 24 semaines<\/li>\n
    • Lupus actif :<\/strong> Doit respecter les seuils d\u2019activit\u00e9 de la maladie bas\u00e9s sur BILAG-2004 et hSLEDAI<\/li>\n
    • Traitement:<\/strong> Actuellement sous au moins l\u2019un des \u00e9l\u00e9ments suivants :\n
        \n
      • Corticost\u00e9ro\u00efdes oraux<\/li>\n
      • Antimalarial<\/li>\n
      • Immunosuppresseur<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

        [\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_2″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

        Principaux crit\u00e8res d\u2019exclusion :<\/strong><\/h6>\n
          \n
        • Thrombose ou embolie r\u00e9cente<\/strong> (dans les 6 mois)<\/li>\n
        • Autres maladies auto-immunes ou inflammatoires<\/strong> (p. ex. psoriasis, scl\u00e9rose syst\u00e9mique)<\/li>\n<\/ul>\n

          [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#6B198A\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2024\/08\/Custom-Gradient-1080×1080@2x.png\u00a0\u00bb custom_margin=\u00a0\u00bb15px||15px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.27.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb15px||15px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

          Pour plus d\u2019informations sur cet essai, veuillez contacter Richmond Clinical Trials.<\/span><\/strong><\/span><\/p>\n

          [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

          Essai clinique sur l\u2019obexelimab pour le lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED)Recrutement actuel de participantsLupus Canada partage de l\u2019information au sujet d\u2019un essai clinique qui recrute actuellement des personnes atteintes de lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED) dans le cadre des essais cliniques de Richmond. Cette \u00e9tude de phase 2 vise \u00e0 \u00e9valuer l\u2019innocuit\u00e9 et la tol\u00e9rabilit\u00e9 de l\u2019Obexelimab, […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[],"topic":[115],"audience":[123,122],"class_list":["post-9690","post","type-post","status-publish","format-standard","hentry","category-article-fr","topic-recherche-et-essais-cliniques","audience-j-ai-le-lupus","audience-j-ai-recemment-recu-un-diagnostic"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=9690"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9690\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=9690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=9690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=9690"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=9690"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=9690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}